Objective: The use of low-dose aspirin (acetylsalicylic acid [ASA]) has been suggested to attenuate growth of abdominal aortic aneurysms (AAAs), yet solid clinical evidence of this hypothesis is still missing. This study aimed to investigate whether preadmission ASA use influenced the risk of presenting with rupture of AAA (rAAA) on hospital admission and subsequent 30-day case fatality. Methods: There were 4010 patients with an incident diagnosis of rAAA and 4010 age-and sex-matched AAA patients identified in the Danish National Registry of Patients. Data on comorbidity, concomitant drug use, primary health care utilization, socioeconomic status, and vital status were obtained from nationwide health care and administrative registries. Results: Preadmission ASA use was identified for 1815 (45.3%) rAAA patients and 2111 (52.6%) AAA patients, corresponding to a crude odds ratio for rAAA in ASA users of 0.72 (95% confidence interval [CI], 0.66-0.79) compared with nonusers. However, after adjustment for possible confounders, no association between ASA use and the risk of rAAA was found (adjusted odds ratio, 0.97; 95% CI, 0.86-1.08). The aggregated 30-day rAAA case-fatality rate for users of ASA was 66.0% compared with 56.9% for nonusers, corresponding to an adjusted mortality rate ratio of 1.16 (95% CI, 1.06-1.27). Conclusions: Preadmission ASA use is not associated with an altered risk of AAA rupture but seems to be associated with a worse prognosis after rupture of AAA. (J Vasc Surg 2017;65:616-25.) 
Although the prevalence of abdominal aortic aneurysm (AAA) has been declining during the last decade, sudden rupture of AAA (rAAA) remains a substantial cause of death in the Western world. [1] [2] [3] [4] An rAAA is a lifethreatening event that typically follows years of growth of an AAA. The current treatment of AAA is surgical (open or endovascular) repair, which is performed when the AAA reaches a size (5.5 cm) at which the annual risk of rupture is considered to exceed the risk of complications after surgical repair. 5, 6 In a majority of AAAs, an intraluminal or mural thrombus is present and the thrombus increases with AAA size. A screening study showed that >40% of AAAs with a size of 3.4 cm in diameter or above had intraluminal thrombi, increasing to 100% prevalence at AAA diameters of above 6.4 cm. 7 The intraluminal thrombus has been found to be biologically active, and it has been suggested that bioactivity within the intraluminal thrombus may influence AAA growth, weaken the aortic wall, and hence increase the risk of rAAA. 8, 9 Furthermore, inhibition of platelet aggregation has been hypothesized to affect the development of the intraluminal thrombus and thus have beneficial effects in attenuating AAA growth. 10 However, contrasting literature exists, suggesting that the presence of an intraluminal thrombus may reduce AAA wall stress and the risk of rAAA. 11 Also, a recent study suggested that the volume of the intraluminal thrombus was comparable in intact and ruptured AAAs. 12 AAA is regarded as an equivalent of coronary heart disease, and consequently treatment with low-dose aspirin (acetylsalicylic acid [ASA]) has been recommended for AAA patients to reduce overall cardiovascular risk. 13, 14 Three smaller studies have suggested that ASA therapy may attenuate growth of AAAs. 7, 15, 16 Also, a recent study suggested ASA therapy to be associated with slower growth of AAA, a lower risk of rupture of AAA, and a reduction of visible mural thrombi in mice with aneurysms. 17 The same study also included a study among AAA patients that showed a lower risk of rupture among ASA users (adjusted hazard ratio, 0.47; 95% confidence interval [CI] , 0.22-1.00). However, large population-based studies of the effect of ASA use on AAAs are still missing. This nationwide, combined case-control and follow-up study aimed to examine the association between ASA use and the risk of presenting with rAAA on hospital admission and subsequent mortality after rAAA.
METHODS
Setting. The Danish health care system is tax financed and uniformly organized. It provides free, unlimited, and equally accessible health care to all citizens (approximately 5.5 million people). Also, partial reimbursement for most prescribed drugs is provided. All contacts to public authorities, including health care services, are registered centrally using a unique, 10-digit civil registration number. This unique identifier, assigned to each individual person at birth or on immigration, allows individual-level and unequivocal linkage of all national health care and administrative registries. 18 rAAA and AAA patients. Data on all patients with an incident hospital discharge diagnosis of rAAA or AAA between January 1, 1996, and December 31, 2012, were extracted from the Danish National Registry of Patients. 19 This register holds data on all somatic admissions to Danish hospitals since 1977 and additionally all outpatient visits since 1995. Discharge diagnoses and surgical procedures performed are registered by the discharging physician using the International Classification of Diseases (revision 8 until 1993, thereafter revision 10) and procedure codes from NOMESCO Classification of Surgical Procedures. The registry has yielded high validity in terms of positive predictive values for a wide range of the most common diseases, including vascular diseases. 20 The positive predictive values of the rAAA and AAA diagnoses in the Danish National Registry of Patients were assessed on the basis of a review of medical records from 3616 patients admitted to a hospital in Western Denmark from 1996 to 2008. A diagnosis of rAAA was considered valid if rupture was either described surgically or verified radiologically by ultrasound or computed tomography scans. An incident AAA diagnosis was confirmed if an infrarenal AAA of $3.0 cm was described on first ultrasound or computed tomography scan. The positive predictive values for the rAAA and AAA diagnoses were 85.7% (95% CI, 83.4-87.9) and 96.3% (95% CI, 95.5-97.0), respectively.
All patients aged 50 years or older were included in the study. Patients with a previous hospital history of rAAA, AAA, or any other aortic disease were excluded. A total of 4532 incident rAAA patients and 18,260 AAA patients were identified. Among these, 477 patients registered with a diagnosis of rAAA who survived 30 days with no record of surgery performed were identified. These patients were excluded as they were likely to have been misclassified. 21 Only six of the remaining patients had endovascular aortic repair. These patients were excluded from the follow-up study to avoid a potential mixture of effects from different treatment regimens. Using risk set sampling, one age-(61 year) and sex-matched AAA patient, diagnosed within 90 days of a corresponding rAAA case patient, was selected from the group of eligible control patients.
Low-dose ASA. ASA is widely used as prophylaxis in cardiovascular disease, and initiation of ASA prophylaxis is recommended for AAA patients on diagnosis to improve their cardiovascular risk profile. In Denmark, ASA is available for cardiovascular prophylaxis in doses ranging between 75 and 150 mg, corresponding to guideline recommendations during the study period. 5, [22] [23] [24] In Denmark, ASA is available both by prescription and as an "over-the-counter" drug. To quantify the use of ASA, data on all prescriptions were obtained from the Register of Medical Products Statistics, which holds complete information, including Anatomical Therapeutic Chemical code, volume, and package size, on all prescriptions filled at Danish pharmacies since 1995. 25, 26 Patients were classified into ASA users (at least one filled prescription in the study period) and nonusers (no filled ASA prescriptions in the study period). The extent of use was assessed in terms of usage years (0-1, 2-3, 4-5, 6-9, and >10 years of use) from the first until the last filled prescription in the study period. The percentage of ASA coverage was calculated as years on ASA treatment divided with the total observation time and grouped in quartiles of increasing ASA coverage.
Covariables. A range of pre-existing diseases, comedications, and inherent baseline characteristics and conditions of the studied patients could potentially confound the association between ASA use and the studied clinical outcomes.
To control for comorbidity, a full hospitalization history for every individual patient was constructed using data from the Danish National Registry of Patients. For the adjusted analyses, the following coexisting diseases were included: myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic pulmonary disease, diabetes, and renal disease. For subanalyses among rAAA cases, surgical procedures performed after admission were extracted. Further for the subanalyses, the medical history for each patient was summarized in Charlson Comorbidity Index (CCI) score. 27 Patients were grouped according to the level of overall comorbidity into low (score of 0), moderate (score of 1-2), and severe (score of $3).
To control for concomitant drug use, a complete medication history since January 1995 was obtained from the Register of Medical Products Statistics. Drug use that could unveil relevant hidden comorbidities not inevitably leading to hospitalization and drug use that could possibly affect growth or size of the AAA and thereby influence the risk of rAAA were of particular interest (eg, statins, antihypertensive drugs, glucose-lowering drugs, and drugs used in asthma and chronic pulmonary diseases). Refer to the Supplementary Material (online only) for codes used from the International Classification of Diseases and Anatomical Therapeutic Chemical codes.
All contacts to the primary health care system in Denmark are registered in the National Health Insurance Service Registry. 28 To control for the effect of doctorseeking behavior, a potential confounder affecting both the risk of having an AAA or rAAA diagnosed and the chance of filling an ASA prescription, data on contacts to a general practitioner (GP) in the year before the index date were retrieved. Patients were categorized in three groups (0-1 contacts, 2-3 contacts, and $4 contacts).
The Civil Registration System provided data on marital and vital status. Data on socioeconomic status was obtained from the Integrated Database for Labour Market Research from Statistics Denmark. 29, 30 The database holds individual-level socioeconomic information on all Danish citizens. On the basis of individual gross income in the year preceding the index date, the patients were classified in quartiles of increasing income.
To explore the impact of aneurysm size on rupture risk, two subgroups of patients were established. The first subgroup contained AAA patients who had elective AAA surgery within 180 days of index date and thus had presumably large and rupture-prone AAAs. The second subgroup contained AAA patients with available data on AAA size at hospital admission. For this subgroup, AAA patients with an AAA diameter measure of $5.5 cm, obtained within 90 days of index date, were identified to explore rupture risk in a group of patients with presumably equal prevalence of intraluminal thrombi and rupture risk.
From another subgroup of the population, data on current tobacco smoking among AAA patients (n ¼ 1348) was retrieved to assess the influence of this potential confounder. The proportion of smokers was 41% among ASA users with AAA and 53% among ASA nonusers with AAA. Furthermore, external data on rAAA risk in smokers compared with nonsmokers were obtained from a metaanalysis by Sweeting et al 31 (risk of rAAA in smokers compared with nonsmokers: hazard ratio, 2.02; 95% CI, 1.33-3.06).
Statistics
Case-control study. The frequencies and proportions of rAAA cases and AAA controls were computed within the different categories of demographic variables, calendar year of diagnosis, ASA use, and possible confounders. A conditional logistic regression model was fitted with adjustment for the covariables (comorbidity, concomitant drug use, contacts to GPs, marital status, and income) to compute crude and adjusted odds ratios with 95% CIs for the association of ASA use and risk of rAAA. In addition, subgroup analyses among the AAA controls with presumably large and rupture-prone AAAs and their corresponding rAAA cases were performed. Also, an external adjustment for unmeasured confounding by tobacco smoking was made. 32 Follow-up study. Frequencies and proportions of ASA use and nonuse were tabulated within the different categories of demographic variables, calendar year of diagnosis, and the described covariables. The rAAA patients were observed from date of admission until death or end of follow-up (30 days), whichever came first. A Cox proportional hazards regression model was fitted to compute crude and adjusted mortality rate ratios (MRRs) with 95% CIs of 30-day mortality among the rAAA cases. The analyses were adjusted for age, sex, calendar year, and the same covariables as used in the case-control study (see earlier). Also, separate estimates of 30-day mortality were computed within strata of different surgical status (6 aortic repair) after admission and across strata of increasing comorbidity level according to CCI score. The proportional hazards assumption was assessed graphically using log-log plots and found appropriate.
Supplementary analyses were conducted across strata of age, sex, calendar year, and visits to GPs to further examine both the risk of rAAA and the prognosis after rAAA. Also, in both the case-control study and the follow-up study, analyses were repeated in subgroups of patients with different degrees of ASA use in terms of usage years and coverage of ASA use in the observation period. Finally, the main analyses were repeated without exclusion of rAAA patients who survived 30 days without surgery and among patients with AAA or rAAA as the leading diagnosis.
All analyses were performed using Stata (StataCorp 2015; Stata Statistical Software: Release 14; StataCorp LP, College Station, Tex). External adjustment was done using a Microsoft Excel spreadsheet (Microsoft, Redmond, Wash) provided by Lash et al. 33, 34 The study was approved by the Danish Data Protection Agency (record No. 2007-58-0010) and the National Board of Health (record No. 7-604-04-2/170/EHE). According to Danish law, registry-based studies do not require informed consent from members of the study population or ethics committee approval.
RESULTS
Risk of rAAA: Case-control study. For the risk analyses, 4010 patients with rAAA (98.9% of the included rAAA patients) were matched 1:1 to 4010 AAA patients (Fig 1) . Men composed 83.4% of the study population; the median age was 74.6 years (interquartile range, 11.8 years). In total, 49.0% of the studied individuals were ASA users on admission with either rAAA or AAA. Detailed characteristics at time of hospital admission are shown in Table I . AAA patients had a substantially higher degree of registered cardiovascular comorbidity than did rAAA cases and had higher rates of filled prescriptions aimed at cardiovascular prophylaxis, including ASA. Also, AAA controls had more contacts to GPs in the year before admission.
ASA users seemed to have a lower risk than nonusers of presenting with rAAA on admission (crude odds ratio, 0.72; 95% CI, 0.66-0.79). However, in adjusting for potential confounders, no association between ASA use and the risk of rAAA was found (adjusted odds ratio, 0.97; 95% CI, 0.86-1.08). Results remained virtually unchanged when stratified according to sex, age, and calendar year of diagnosis. Despite more GP visits among the AAA controls, no difference in the risk of rAAA was observed across strata of visits to GPs. Analyses of ASA usage according to years of use and coverage of ASA use yielded comparable results. The subgroup analyses considering control patients with large or rupture-prone AAAs comprised 338 AAA patients with AAA diameter of $5.5 cm and 1026 AAA patients with elective AAA surgery within 180 days of index date. In accordance with the main results, the estimates of rupture risk comparing these two groups of AAA controls to their corresponding rAAA cases showed no association between ASA use and risk of rAAA (Fig 2) . The external adjustment for tobacco smoking also left the association virtually unchanged with an adjusted odds ratio of 1.04 (95% CI, 0.93-1.17) for ASA use.
Thirty-day case-fatality rate: Follow-up study. Complete follow-up was available for 4036 rAAA cases (99.5% of the included cases). Baseline characteristics are shown in Table II . ASA users were older and had a considerably heavier burden of cardiovascular and other comorbidity. Also, more ASA users had redeemed drug Denmark, 1996 Denmark, -2012 . AAA, Abdominal aortic aneurysm; CI, confidence interval; OR, odds ratio. (a) Adjusted for calendar interval, comorbidity (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic pulmonary disease, diabetes mellitus, renal disease), current use of other drugs (clopidogrel, statins, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium antagonists, antidiabetic therapy, and drugs against chronic obstructive pulmonary disease), contacts to a general practitioner (GP) in the year before admission (0-1 contacts, 2-3 contacts, 4 or more contacts), marital status (married, divorced or widowed, never married or unknown), and gross income in quartiles. change the estimates (adjusted MRR, 1.16; 95% CI, 1.06-1.27). The results were persistent in the analyses stratified according to sex, age, calendar year of diagnosis, and GP visits. Also, the subgroup analyses based on ASA usage yielded similar results. Not surprisingly, the stratified analysis on surgical status showed that rAAA patients without any aortic repair on admission had poor survival regardless of ASA therapy. Still, preadmission ASA therapy was associated with a higher 30-day case-fatality rate among rAAA patients who had attempted aortic repair on admission (Supplementary  Table and Supplementary Fig, online only) . The analyses stratified according to comorbidity level were in accordance with the primary analyses (Fig 3) . Repeating the analyses without exclusion of potentially misclassified rAAA patients and by including only patients with a leading AAA or rAAA diagnosis also did not change the risk estimates (data not shown).
DISCUSSION
In this large, population-based study, no association between use of ASA and the risk of presenting with rAAA on hospital admission was found. However, ASA use was associated with a poorer 30-day prognosis after rAAA.
The results of this study are in contrast to a recently published study by Owens et al 17 that suggested a reduced rupture risk in ASA users. However, the results are not directly comparable as Owens et al did not differentiate Denmark, 1996 Denmark, -2012 . CI, Confidence interval; MRR, mortality rate ratio. (a) Adjusted for calendar interval, comorbidity (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic pulmonary disease, diabetes mellitus, renal disease), current use of other drugs (clopidogrel, statins, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium antagonists, antidiabetic therapy, and drugs against chronic obstructive pulmonary disease), contacts to a general practitioner (GP) in the year before admission (0-1 contacts, 2-3 contacts, 4 or more contacts), marital status (married, divorced or widowed, never married or unknown), and gross income in quartiles. between rupture and dissection of AAAs. Also, the study included only 22.7% (or roughly 80 patients) with AAA, the rest having either thoracoabdominal or thoracic aneurysms.
The finding of an adverse outcome in ASA users after rAAA has not previously been reported. In this study, only patients who had open surgical repair or no repair after rAAA were considered. The adverse outcome after rAAA among ASA users could likely relate to complications of excessive bleeding due to ASA-induced altered coagulation or ineffective clotting in the immediate perioperative period after rAAA. However, a randomized controlled trial studying ASA use and perioperative mortality in noncardiac surgery reported no excess in 30-day mortality despite the finding of an increased risk of major bleeding in ASA users. 35 In an observational follow-up study among vascular surgery patients, reduced 30-day and 5-year mortalities were suggested for patients receiving antiplatelet therapy. 36 The major strength of this study is the populationbased design in a uniformly organized system with highly reliable health care and administrative registries and virtually complete follow-up. The unambiguous, individuallevel linkage of the prospectively collected data allowed comprehensive confounder control. Free and equal access to the health care system limited the extent of selection bias in this study to a minimum. However, only rAAA and AAA patients able to reach the hospital alive were included in the study, leaving a potential for selection bias especially among the rAAA patients.
A potential limitation is the risk of misclassification of ASA use. The filling of an ASA prescription is a proxy measure of ASA use. Furthermore, ASA is available over the counter in many grocery stores and pharmacies as well as by prescription. This leaves a potential for underestimation of the actual ASA use as only data on filled prescriptions were available. Nonusers could thus in theory be users and actual users could have used even more ASA than revealed in looking at prescription data only. A misclassification of this kind would most likely be nondifferential among cases and controls and would consequently tend to drive the estimates toward a null association. The magnitude of this problem has previously been assessed by looking at the percentage of prescription sale compared with the total sale of ASA. In Denmark, the percentage of prescription sale compared with the total sale of ASA increased from 62% to 92% from 1999 to 2012. 37 To further elucidate the effect of this probable misclassification, analyses stratified on calendar year of diagnosis were performed. Given that the results remained virtually unchanged across strata of calendar periods, it seems unlikely that misclassification of ASA use has had any substantial impact on the results of the overall analysis.
Another potential limitation is the missing data on tobacco smoking among the rAAA patients. Tobacco smoking is known to double the risk of rAAA. 31 The magnitude of this potential factor was examined by external adjustment and showed that unmeasured smoking was unlikely to have had any substantial impact on the study findings. Furthermore, only limited data on AAA size were available in this study, leaving a potential for unmeasured confounding. A large AAA diameter (and subsequent prevalence of an intraluminal thrombus) is associated with a higher rupture risk and could thus influence the results. 38 However, subgroup analyses restricted to large and presumably rupture-prone AAAs did not differ substantially from the primary findings. Still, future studies considering the impact of ASA use on AAA growth may be warranted.
In the follow-up study, ASA users had a higher degree of cardiovascular comorbidity. This could possibly have affected the observed poorer prognosis after rAAA for this group. However, in the adjusted analyses, the poorer 30-day prognosis remained. Also, stratification on CCI score yielded comparable results. Still, the possibility that ASA use is a marker of sicker patients with an inherently poor prognosis cannot be excluded. Clinical data on other potentially important confounding factors (ie, blood pressure, renal function, and acute cardiac ischemia) were unfortunately unavailable, and this leaves a potential for residual confounding, especially in the follow-up study, in which comorbidity of this kind might have affected study outcomes. Also, no data on magnitude of blood loss or numbers of blood transfusions administered were available to elucidate whether excessive perioperative bleeding could explain the findings.
CONCLUSIONS
In this study, preadmission ASA use did not change the risk of rAAA but was associated with a higher mortality after rAAA. However, these results do not provide sufficiently strong evidence to recommend against the use of ASA in patients with asymptomatic AAAs, given that the anticipated general cardiovascular protective effect is considered to outweigh the risk of an adverse outcome if the patient should suffer an rAAA. 
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